Abstract

Herpes simplex encephalitis (HSE) is a life-threatening complication of herpes simplex virus (HSV) infection. Acyclovir (ACV) is the antiviral treatment of choice, but may lead to emergence of ACV-resistant (ACVR) HSV due to mutations in the viral UL23 gene encoding for the ACV-targeted thymidine kinase (TK) protein. Here, we determined the prevalence of intrathecal ACVR–associated HSV TK mutations in HSE patients and compared TK genotypes of sequential HSV isolates in paired cerebrospinal fluid (CSF) and blister fluid of mucosal HSV lesions. Clinical samples were obtained from 12 HSE patients, encompassing 4 HSV type 1 (HSV-1) and 8 HSV-2 encephalitis patients. HSV DNA load was determined by real-time PCR and complete HSV TK gene sequences were obtained by nested PCR followed by Sanger sequencing. All HSV-1 HSE patients contained viral TK mutations encompassing 30 unique nucleotide and 13 distinct amino acid mutations. By contrast, a total of 5 unique nucleotide and 4 distinct amino acid changes were detected in 7 of 8 HSV-2 patients. Detected mutations were identified as natural polymorphisms located in non-conserved HSV TK gene regions. ACV therapy did not induce the emergence of ACVR-associated HSV TK mutations in consecutive CSF and mucocutaneous samples of 5 individual patients. Phenotypic susceptibility analysis of these mucocutaneous HSV isolates demonstrated ACV-sensitive virus in 2 HSV-1 HSE patients, whereas in two HSV-2 HSE patients ACVR virus was detected in the absence of known ACVR-associated TK mutations. In conclusion, we did not detect intrathecal ACVR-associated TK mutations in HSV isolates obtained from 12 HSE patients.

Highlights

  • Herpes simplex encephalitis (HSE) is a rare life-threatening complication of infection with herpes simplex virus type 1 (HSV-1) and HSV-2

  • ACV therapy refractory HSE case reports with intrathecal ACVR HSV have been described [13,14,15,16], the prevalence of intrathecal ACVR HSV-1 and HSV-2 in HSE patients is unknown

  • The current study showed that intrathecal ACVR-associated HSV thymidine kinase (TK) mutations are uncommon in a cohort of clinically unbiased HSV-1 (n = 4) and HSV-2 (n = 8) HSE patients and do not appear to develop intrathecally

Read more

Summary

Introduction

Herpes simplex encephalitis (HSE) is a rare life-threatening complication of infection with herpes simplex virus type 1 (HSV-1) and HSV-2. HSE affects 1 in 250,000 to 500,000 persons per year in the USA and comprises about one-fifth of all encephalitis cases in the UK [1,2]. HSV-1 causes 90% of HSE cases in immunocompetent adults, whereas HSV-2-associated HSE is more. Acyclovir Resistance in HSV Encephalitis Patients common in neonates and immunocompromised individuals [2,3]. Prompt diagnosis, based on magnetic resonance imaging of the brain and detection of HSV DNA in cerebrospinal fluid (CSF) by PCR, and preemptive administration of antiviral drugs are pivotal to reduce HSEinduced morbidity and mortality [2,3,4]. Mortality from HSE is about 70% in untreated patients, which is reduced to 11% to 19% when immediate antiviral therapy is provided [1,5]. Approximately 12% to 60% of treated HSE patients develop neurological sequelae [1,5]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call